Hydrocodone Gets Advisory Committee Review, Offering Congress A Scheduling Out
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA announces the October meeting unusually early following legislative efforts to further restrict access to the opioid pain reliever due to abuse worries.